PRPH
ProPhase Labs, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.02
+17.65%Margins
Gross margin
16.4%
EBITDA margin
-226.5%
EBIT margin
-498.7%
Net margin
-717.4%
FCF margin
-972.3%
727.8%
Return on equity
-39.4%
Return on assets
-261.9%
Return on invested capital
0.05x
Asset turnover
-$30.7M
Cash from operations
$0.00
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026